Abstract
Pseudomonas aeruginosa is a multidrug-resistant Gram-negative pathogen and one of the leading causes of ventilator-associated pneumonia and infections in patients with chronic obstructive pulmonary disease and cystic fibrosis. Murepavadin is a peptidomimetic that specifically targets outer-membrane lipopolysaccharide transport protein LptD of P. aeruginosa. In this study, we find that murepavadin enhances the bactericidal efficacy of ciprofloxacin. We further demonstrate that murepavadin increases intracellular accumulation of ciprofloxacin by suppressing drug efflux. In addition, the murepavadin–ciprofloxacin combination exhibits a synergistic bactericidal effect in an acute murine pneumonia model. In conclusion, our results identify an effective drug combination for the treatment of P. aeruginosa infections.
Funding Information
  • National Key Research and Development Program of China (2021YFE0101700, 32170177, 32170199, 22JCZDJC0041)
  • National Science Foundation of China (2021YFE0101700, 32170177, 32170199, 22JCZDJC0041)
  • Nankai University Tianjin Applied and Fundamental Research Project (2021YFE0101700, 32170177, 32170199, 22JCZDJC0041)

This publication has 58 references indexed in Scilit: